Dimethyl fumarate (DMF), a well-known NRF2 activator approved for clinical use in treating psoriasis and multiple sclerosis, has demonstrated significant efficacy by modulating oxidative stress and immune responses through NRF2 pathway activation [66,89]. Here, NFE2L2 is linked to multiple sclerosis.